Literature DB >> 23092278

From the chemistry of epoxy-sugar nucleosides to the discovery of anti-HIV agent 4'-ethynylstavudine-Festinavir.

Kazuhiro Haraguchi1, Shingo Takeda, Yutaka Kubota, Hiroki Kumamoto, Hiromichi Tanaka, Takayuki Hamasaki, Masanori Baba, Elijah Paintsil, Yung-Chi Cheng.   

Abstract

Branched sugar nucleosides have attracted much attention due to their biological activities. We have demonstrated that epoxysugar nucleosides serve as versatile precursor for the stereo-defined synthesis of these nucleoside derivatives on the basis of its ring opening with organoaluminum or organosilicon reagents. In this review article, novel methods for the synthesis of nucleoside analogues branched at the 1' and 4'-position will be described. During this study, we could discover an anti-HIV agent, 4'-ethynylstavudine (Festinavir). Festinavir showed more potent anti-HIV activity than the parent compound stavudine (d4T). Other significant properties of Festinavir are as follows: 1) much less toxic to various cells and also to mitochondorial DNA synthesis than d4T, 2) better substrate for human thymidine kinase than d4T, 3) resistant not only to chemical glycosidic bond cleavage but also to catabolism by thymidine phosphorylase, 4) the activity improves in the presence of a major mutation, K103N, associated with resistance to non-nucleoside reverse transcriptase inhibitors. Detailed profile of the antiviral activities, biology and pharmacology of Festinavir are also described.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23092278      PMCID: PMC3711117          DOI: 10.2174/1381612811319100011

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  46 in total

1.  The synthesis of some branched-chain-sugar nucleoside analogues.

Authors:  M Ashwell; A S Jones; R T Walker
Journal:  Nucleic Acids Res       Date:  1987-03-11       Impact factor: 16.971

2.  Nucleosides and nucleotides. 158. 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)-cytosine, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)uracil, and their nucleobase analogues as new potential multifunctional antitumor nucleosides with a broad spectrum of activity.

Authors:  H Hattori; M Tanaka; M Fukushima; T Sasaki; A Matsuda
Journal:  J Med Chem       Date:  1996-12-06       Impact factor: 7.446

3.  Syntheses of 4'-C-ethynyl-beta-D-arabino- and 4'-C-ethynyl-2'-deoxy-beta-D-ribo-pentofuranosylpyrimidines and -purines and evaluation of their anti-HIV activity.

Authors:  H Ohrui; S Kohgo; K Kitano; S Sakata; E Kodama; K Yoshimura; M Matsuoka; S Shigeta; H Mitsuya
Journal:  J Med Chem       Date:  2000-11-16       Impact factor: 7.446

Review 4.  Sugar-modified nucleosides in past 10 years, a review.

Authors:  E Ichikawa; K Kato
Journal:  Curr Med Chem       Date:  2001-03       Impact factor: 4.530

5.  Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.

Authors:  R F Schinazi; R M Lloyd; M H Nguyen; D L Cannon; A McMillan; N Ilksoy; C K Chu; D C Liotta; H Z Bazmi; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

6.  Synthesis of a highly active new anti-HIV agent 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine.

Authors:  Kazuhiro Haraguchi; Shingo Takeda; Hiromichi Tanaka; Takao Nitanda; Masanori Baba; G E Dutschman; Yung-Chi Cheng
Journal:  Bioorg Med Chem Lett       Date:  2003-11-03       Impact factor: 2.823

7.  Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.

Authors:  Guangwei Yang; Elijah Paintsil; Ginger E Dutschman; Susan P Grill; Chuan-Jen Wang; Jimin Wang; Hiromichi Tanaka; Takayuki Hamasaki; Masanori Baba; Yung-Chi Cheng
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

8.  Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.

Authors:  Atsuko Hachiya; Eiichi N Kodama; Stefan G Sarafianos; Matthew M Schuckmann; Yasuko Sakagami; Masao Matsuoka; Masafumi Takiguchi; Hiroyuki Gatanaga; Shinichi Oka
Journal:  J Virol       Date:  2008-01-23       Impact factor: 5.103

9.  Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

Authors:  T Shirasaka; M F Kavlick; T Ueno; W Y Gao; E Kojima; M L Alcaide; S Chokekijchai; B M Roy; E Arnold; R Yarchoan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205

Review 10.  The design of drugs for HIV and HCV.

Authors:  Erik De Clercq
Journal:  Nat Rev Drug Discov       Date:  2007-12       Impact factor: 84.694

View more
  4 in total

1.  In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.

Authors:  Zhufang Li; Brian Terry; William Olds; Tricia Protack; Carol Deminie; Beatrice Minassian; Beata Nowicka-Sans; Yongnian Sun; Ira Dicker; Carey Hwang; Max Lataillade; George J Hanna; Mark Krystal
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

2.  From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection.

Authors:  Shalley N Kudalkar; Jagadish Beloor; Elias Quijano; Krasimir A Spasov; Won-Gil Lee; José A Cisneros; W Mark Saltzman; Priti Kumar; William L Jorgensen; Karen S Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-26       Impact factor: 11.205

Review 3.  Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.

Authors:  Joel da Cunha; Luciana Morganti Ferreira Maselli; Ana Carolina Bassi Stern; Celso Spada; Sérgio Paulo Bydlowski
Journal:  World J Virol       Date:  2015-05-12

Review 4.  Investigational reverse transcriptase inhibitors for the treatment of HIV.

Authors:  Theodore J Cory; Narasimha M Midde; Pss Rao; Santosh Kumar
Journal:  Expert Opin Investig Drugs       Date:  2015-06-19       Impact factor: 6.206

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.